Chosen markers of inflammation in inflammatory bowel diseases;Wybrane markery stanu zapalnego w nieswoistych zapaleniach jelit

Gastroenterologia Polska

Volumn 14, Issue 6, 2007, Pages 429-431

  Eder, Piotr ^a   Stawczyk, Kamila ^a   Krela Kaźmierczak, Iwona ^a,b   Linke, Krzysztof ^a  

^a Katedra I Klinika Gastroenterologii

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Inflammatory markers; Le niowski Crohn's disease; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA;

ENTERITIS; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW;

EID: 38349075319     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Abreu M.T., Sparrow M.P.: Translational research in inflammatory bowel disease. Mt Sinai J. Med., 2006, 78, 1067-1072.
2. Hendrickson B.A., Gokhale R., Cho J.H.: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev., 2002, 15, 79-94.
3. Monteleone G., Fina D., Caruso R., Pallone F.: New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol., 2006, 22, 361-364.
4. Kowalczyk J.: Professor Edmund Biernacki (1866-1911) and the discovery of the erythrocyte sedimentation rate. S. Afr. Med. J., 2006, 96, 40-41.
5. Brigden M.L.: Clinical utility of the erythrocyte sedimentation rate. Am. Fam. Physician., 1999, 60, 1443-1455.
6. Vermeire S., Van Assche G., Rutgeerts P.: Laboratory markers in inflammatory bowel disease: useful, magic, or unnecessary toys? Gut, 2006, 55, 426-431.
7. Solnica B.: Białko C-reaktywne. [w:] Choroby wewnȩtrzne, (red.) A. Szczeklik. Medycyna Praktyczna, Kraków 2005, 33-34.
8. Gisbert J.P., Gonzalez-Lama Y., Mate J.: Role of biological markers in inflammatory bowel disease. Gastroenterol. Hepatol., 2007, 30, 117-129.
9. Stevens C., Walz G., Singaram C., Lipman M.L., Zanker B., Muqqia A., Antonioli D., Peppercorn M.A., Strom T.B.: Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig. Dis. Sci., 1992, 37, 818-826.
10. Holtkamp W., Stollberg T., Reis H.E.: Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J. Clin. Gastroenterol., 1995, 20, 123-126.
11. Podolsky D.K.: Inflammatory bowel disease. N. Engl. J. Med., 2002, 347, 417-429.
12. Goła̧ b J., Jakóbisiak M., Zagożdżon R., Obła̧kowski P.: Cytokiny. [w:] Immunologia, (red.) J. Goła̧b, M. Jakóbisiak, W. Lasek. Wydawnictwo Naukowe PWN, Warszawa 2004, 236-248.
13. Dionne S., Hiscott J., D'agata I., Duhaime A., Seidman E.G.: Quantitative PCR analysis of tumor necrosis factor-alpha and interleukin-1beta mRNA levels in pediatric inflammatory bowel disease mucosal biopsies. Dig. Dis. Sci., 1997, 42, 1557-1566.
14. Mazlam M.Z., Hodgson H.J.: Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut, 1992, 33, 773-778.
15. Hyams J.S., Treem W.R., Eddy E., Wyzga N., Moore R.E.: Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr., 1991, 12, 233-236.
16. Komatsu M., Kobayashi D., Saito K., Furuya D., Yagihashi A., Araake H., Tsuji N., Sakamaki S., Niitsu Y., Watanabe N.: Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by highly sensitive immuno-PCR. Clin. Chem., 2001, 47, 1297-1301.
17. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y.: Increased expression of interleukin-17 in inflammatory bowel disease. Gut, 2003, 52, 65-70.
18. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., Mckenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., Rennick D.: Interleukin-23 is essential for T cell-mediated colitis and promotes inflammation via interleukin-17 and interleukin-6. J. Clin. Invest., 2006, 116, 1310-1316.
19. Trinchieri G.: Interleukin-12 and regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol., 2003, 3, 133-146.
20. Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., Rennick D.M.: Interleukin-12, but not interferon-gamma, plays a major role in sustaining the chronic phase of colitis in interleukin-10-deficient mice. J. Immunol., 1998, 161, 3143-3149.
21. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., Dolin B., Goodman N., Groden C., Hornung R.L., Quezado M., Yang Z., Neurath M.F., Salfeld J., Veldman G.M., Schwertschlag U., Stober W.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med., 2004, 351, 2069-2079.
22. Noguchi M., Hiwatashi N., Liu Z., Toyota Z.: Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut, 1998, 43, 203-209.
23. Nakamura K., Honda K., Mizutani T., Akiho H., Harada N.: Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J. Gastroenterol., 2006, 12, 4628-4635.
24. Jeejeebhoy R.W., Coghill N.F.: The measurement of gastrointestinal protein loss by a new method. Gut, 1961, 2, 123-130.
25. Yui S., Nakatani Y., Mikami M.: Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol. Pharm. Bull., 2003, 26, 753-760.
26. Tibble J., Bjarnason I.: Non-invasive investigation of inflammatory bowel disease. World J. Gastroenterol., 2001, 7, 460-465.
27. Tibble J., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I.: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology, 2000, 119, 15-22.